Research news
Parkinson’s UK has funded two future leaders in Parkinson’s research who are pushing forward our understanding of the early stages and causes of Parkinson’s.
Early research shows transplanting gut bacteria from healthy individuals to people with Parkinson’s, called a faecal microbiota transplant, is safe and may ease motor symptoms.
Lixisenatide, a diabetes drug being investigated for Parkinson’s, shows potential to slow the progression of movement symptoms.
New research study shows impact of delirium for people with Parkinson’s in hospital
The simple skin test was able to detect a troublesome protein associated with Parkinson's and other similar conditions.
Our latest round of grants fund projects which aim to improve everyday life for people living with Parkinson’s, without the need for extra medications.
Foslevodopa-foscarbidopa (also called Produodopa) has been approved by NICE in England, Northern Ireland and Wales and the Scottish Medicines Consortium for people with Parkinson’s who experience movement related symptoms.
Foslevodopa-foscarbidopa (also called Produodopa) can be offered in England from 27 February for people with Parkinson’s who experience movement related symptoms.
A further trial of a device-delivered GDNF is not going ahead, but other approaches are showing promise.
Predict-PD is a study that aims to understand the risk factors of Parkinson’s. More than 10,000 people are now taking part and are representative of the ethnic diversity within the UK population.